• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

门脉高压症中的非选择性β受体阻滞剂：为何、何时以及如何应用？

Nonselective Beta-Blockers in Portal Hypertension: Why, When, and How?

作者信息

Rabiee Anahita, Garcia-Tsao Guadalupe, Tapper Elliot B

机构信息

Digestive Diseases Section Yale School of Medicine New Haven CT.

Digestive Diseases Section VA-CT Healthcare System West Haven CT.

出版信息

Clin Liver Dis (Hoboken). 2022 Mar 8;19(3):118-123. doi: 10.1002/cld.1182. eCollection 2022 Mar.

DOI:10.1002/cld.1182
PMID:35355838
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8958249/
Abstract

Content available: Author Interview and Audio Recording.

摘要

可获取的内容

作者访谈及音频记录。

相似文献

1
Nonselective Beta-Blockers in Portal Hypertension: Why, When, and How?门脉高压症中的非选择性β受体阻滞剂：为何、何时以及如何应用？
Clin Liver Dis (Hoboken). 2022 Mar 8;19(3):118-123. doi: 10.1002/cld.1182. eCollection 2022 Mar.
2
β-arrestin-2 predicts the clinical response to β-blockers in cirrhotic portal hypertension patients: A prospective study.β-抑制蛋白2预测肝硬化门静脉高压患者对β受体阻滞剂的临床反应：一项前瞻性研究。
World J Hepatol. 2022 Feb 27;14(2):429-441. doi: 10.4254/wjh.v14.i2.429.
3
Prevention of Variceal Bleeding and Rebleeding by Nonselective Beta-Blockers: A Tailored Approach.非选择性β受体阻滞剂预防静脉曲张出血和再出血：一种量身定制的方法。
Clin Liver Dis. 2021 May;25(2):311-326. doi: 10.1016/j.cld.2021.01.004. Epub 2021 Mar 10.
4
Portal pressure reductions induced by nonselective beta-blockers improve outcomes and decrease mortality in patients with cirrhosis with and without ascites.非选择性β受体阻滞剂引起的门静脉压力降低可改善肝硬化伴或不伴腹水患者的预后并降低死亡率。
Clin Liver Dis (Hoboken). 2022 Jun 3;20(1):1-4. doi: 10.1002/cld.1210. eCollection 2022 Jul.
5
The Beneficial Effect of Beta-Blockers in Patients With Cirrhosis, Portal Hypertension and Ascites.β受体阻滞剂对肝硬化、门静脉高压和腹水患者的有益作用。
Am J Med Sci. 2016 Feb;351(2):169-76. doi: 10.1016/j.amjms.2015.11.018.
6
Nonselective beta-blockers and the risk of portal vein thrombosis in patients with cirrhosis: results of a prospective longitudinal study.非选择性β受体阻滞剂与肝硬化患者门静脉血栓形成风险：一项前瞻性纵向研究的结果。
Aliment Pharmacol Ther. 2019 Mar;49(5):582-588. doi: 10.1111/apt.15137. Epub 2019 Jan 22.
7
Selective versus nonselective beta adrenoceptor antagonists in hypertension.高血压治疗中选择性与非选择性β肾上腺素能受体拮抗剂的比较
Pharmacoeconomics. 1995 Dec;8(6):513-23. doi: 10.2165/00019053-199508060-00006.
8
Pharmacological treatment of portal hypertension: hemodynamic effects and prevention of bleeding.门静脉高压的药物治疗：血流动力学效应及出血预防
Pharmacol Ther. 1994;61(1-2):65-107. doi: 10.1016/0163-7258(94)90059-0.
9
Use of ß-blocker therapy to prevent primary bleeding of esophageal varices.使用β受体阻滞剂疗法预防食管静脉曲张的初次出血。
J Am Acad Nurse Pract. 2010 Dec;22(12):640-7. doi: 10.1111/j.1745-7599.2010.00567.x. Epub 2010 Nov 9.
10
Long-term pharmacologic therapy of portal hypertension.门静脉高压症的长期药物治疗
Surg Clin North Am. 1990 Apr;70(2):319-39. doi: 10.1016/s0039-6109(16)45084-x.

引用本文的文献

1
From Pathophysiology to Practice: Evolving Pharmacological Therapies, Clinical Complications, and Pharmacogenetic Considerations in Portal Hypertension.从病理生理学到临床实践：门静脉高压症不断发展的药物治疗、临床并发症及药物遗传学考量
Metabolites. 2025 Jan 23;15(2):72. doi: 10.3390/metabo15020072.
2
Non-cirrhotic portal hypertension in pregnancy due to schistosomiasis: A case series.血吸虫病所致妊娠合并非肝硬化门静脉高压症：病例系列报道
Obstet Med. 2025 Jun;18(2):107-113. doi: 10.1177/1753495X241241833. Epub 2024 Apr 17.
3
Relationship between platelet-to-lymphocyte ratio and early rebleeding after endoscopic variceal ligation: a bicenter retrospective study.血小板与淋巴细胞比值与内镜下食管静脉曲张套扎术后早期再出血的关系：一项双中心回顾性研究。
Ann Med. 2024 Dec;56(1):2400315. doi: 10.1080/07853890.2024.2400315. Epub 2024 Sep 6.
4
Examining the therapeutic landscape of beta-blockers in portal hypertension.审视β受体阻滞剂在门静脉高压症中的治疗前景。
Clin Mol Hepatol. 2024 Oct;30(4):1055-1059. doi: 10.3350/cmh.2024.0144. Epub 2024 Mar 6.
5
Keep beta-blocking and carry on!持续使用β受体阻滞剂并继续治疗！
Clin Liver Dis (Hoboken). 2024 Jan 31;23(1):e0114. doi: 10.1097/CLD.0000000000000114. eCollection 2024 Jan-Jun.
6
Portal Hypertension in Malnutrition and Sarcopenia in Decompensated Cirrhosis-Pathogenesis, Implications and Therapeutic Opportunities.失代偿期肝硬化的营养不良和肌肉减少症相关门静脉高压症的发病机制、影响及治疗机会
Nutrients. 2023 Dec 21;16(1):35. doi: 10.3390/nu16010035.
7
Pharmacotherapies for Portal Hypertension: Current Status and Expanding Indications.门静脉高压的药物治疗：现状与适应证拓展
Curr Hepatol Rep. 2023 Mar;22(1):44-50. doi: 10.1007/s11901-023-00600-z. Epub 2023 Feb 20.
8
Compensated liver cirrhosis: Natural course and disease-modifying strategies.代偿期肝硬化：自然病程及疾病修饰策略
World J Methodol. 2023 Sep 20;13(4):179-193. doi: 10.5662/wjm.v13.i4.179.

本文引用的文献

1
Test-Retest Reliability and Consistency of HVPG and Impact on Trial Design: A Study in 289 Patients from 20 Randomized Controlled Trials.肝静脉压力梯度（HVPG）的复测可靠性和一致性及其对试验设计的影响：来自 20 项随机对照试验的 289 例患者的研究。
Hepatology. 2021 Dec;74(6):3301-3315. doi: 10.1002/hep.32033. Epub 2021 Aug 15.
2
Non-selective beta-blockers impair global circulatory homeostasis and renal function in cirrhotic patients with refractory ascites.非选择性β受体阻滞剂会损害顽固性腹水肝硬化患者的整体循环稳态和肾功能。
J Hepatol. 2020 Dec;73(6):1404-1414. doi: 10.1016/j.jhep.2020.05.011. Epub 2020 May 21.
3
Systemic arterial blood pressure determines the therapeutic window of non-selective beta blockers in decompensated cirrhosis.全身动脉血压决定失代偿期肝硬化中非选择性β受体阻滞剂的治疗窗。
Aliment Pharmacol Ther. 2019 Sep;50(6):696-706. doi: 10.1111/apt.15439. Epub 2019 Aug 2.
4
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.β 受体阻滞剂预防有临床显著门静脉高压症的肝硬化失代偿（PREDESCI）：一项随机、双盲、安慰剂对照、多中心试验。
Lancet. 2019 Apr 20;393(10181):1597-1608. doi: 10.1016/S0140-6736(18)31875-0. Epub 2019 Mar 22.
5
Cardiopulmonary hemodynamics and C-reactive protein as prognostic indicators in compensated and decompensated cirrhosis.心肺血液动力学和 C 反应蛋白作为代偿性和失代偿性肝硬化的预后指标。
J Hepatol. 2018 May;68(5):949-958. doi: 10.1016/j.jhep.2017.12.027. Epub 2018 Jan 10.
6
Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases.肝硬化门静脉高压出血：风险分层、诊断及管理：美国肝病研究协会2016年实践指南
Hepatology. 2017 Jan;65(1):310-335. doi: 10.1002/hep.28906. Epub 2016 Dec 1.
7
Nonselective β-Blockers and Survival in Patients With Cirrhosis and Ascites: A Systematic Review and Meta-analysis.非选择性β受体阻滞剂与肝硬化伴腹水患者生存：系统评价和荟萃分析。
Clin Gastroenterol Hepatol. 2016 Aug;14(8):1096-1104.e9. doi: 10.1016/j.cgh.2016.01.012. Epub 2016 Jan 30.
8
Development of hyperdynamic circulation and response to β-blockers in compensated cirrhosis with portal hypertension.高动力循环的发展和对伴有门脉高压的代偿性肝硬化的β受体阻滞剂的反应。
Hepatology. 2016 Jan;63(1):197-206. doi: 10.1002/hep.28264. Epub 2015 Nov 26.
9
Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis.非选择性β受体阻滞剂治疗可降低肝硬化患者的肠通透性和血清 LBP、IL-6 水平。
J Hepatol. 2013 May;58(5):911-21. doi: 10.1016/j.jhep.2012.12.011. Epub 2012 Dec 20.
10
Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol.卡维地洛治疗普萘洛尔治疗反应不佳的肝硬化患者原发性预防静脉曲张出血。
Gut. 2013 Nov;62(11):1634-41. doi: 10.1136/gutjnl-2012-304038. Epub 2012 Dec 18.